J&J Wins Dismissal of Pennsylvania Risperdal Lawsuit
This article is for subscribers only.
Johnson & Johnson won dismissal of Pennsylvania’s suit alleging that the drugmaker hid health risks of its Risperdal antipsychotic drug and duped officials into paying millions more than they should have for the medicine.
Judge Frederica Massiah-Jackson in Philadelphia today granted the company’s request to throw out the suit after finding the state hadn’t produced enough evidence the company improperly marketed Risperdal to continue the trial. State lawyers had presented a week’s testimony to jurors.